Lilly claims that the weight loss drug Mounjaro has been approved for sale in Hong Kong
海角七号
发表于 2024-10-28 10:08:31
166
0
0
On October 28, Lilly said in a statement that it had obtained the approval of the Hong Kong SAR government to sell its Tirzepatide injection (trade name: Mounjaro) through a device called Kwikpen (pre filled injection pen) for long-term weight management and type 2 diabetes. Lilly is expected to start selling this weight loss medication in Hong Kong as early as the end of this year. (Bloomberg)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- AstraZeneca elontersen approved in the United States
- Novo Nordisk plans to introduce weight loss oral small molecule drugs for 235 million euros
- Approval of new indications for Mercado Pembrolizumab
- AstraZeneca IL-5R α monoclonal antibody approved for market in China
- AstraZeneca and Sinopharm Group reach nearly $2 billion cardiovascular drug authorization agreement
- Johnson&Johnson's drug Zebaike has been approved in China
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Merck antifungal drug Noclof é l? New indications approved